Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate;...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of MRSN is 31 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell